Aligos Therapeutics

Historical price data

Aligos Therapeutics is a clinical-stage biotech focused on developing best-in-class therapies for chronic liver and viral diseases, specifically chronic hepatitis B (CHB) and MASH. The company employs a targeted, chemistry-driven approach to design small molecules with optimized pharmacological profiles. Its strategy centers on a lean, experienced team with a proven track record in hepatology and virology drug development, aiming to advance a focused pipeline through key clinical milestones. Despite a challenging financial position with a low market valuation, its progress is defined by upcoming Phase 2 data for its lead assets.

A chemistry-driven approach leveraging deep expertise in medicinal chemistry and disease biology to design optimized small molecule drugs for viral and liver diseases, without a single proprietary technological platform.

In CHB, Pevifoscorvir competes with other capsid assembly modulators, siRNA, and antisense therapies in pursuit of a curative regimen. In MASH, ALG-055009 enters a validated but competitive field against the approved Resmetirom and other late-stage THR-β agonists and novel mechanisms.